GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Gain Therapeutics GANX · USD

N/A · US listing · 🇺🇸 United States

Compare

1.09

+5.83%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2018FY2025

Net income

−$20.2m

FY2018FY2025

Free cash flow

−$18.5m

FY2018FY2025

Shareholders' equity

$18.6m

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue——$55,180$140,108$164,994$28,881$41,301$20,609
Gross profit−$94,046−$84,071$55,180$140,108$164,994$28,881$41,301$20,609
Research and development$10.2m$10.8m$11.5m$8.4m$7.2m$2.3m$1.6m$826,880
Operating income−$18.7m−$20.4m−$22.3m−$17.8m−$13.8m−$3.5m−$2.1m−$1.0m
Net income−$20.2m−$20.4m−$22.3m−$17.6m−$13.9m−$3.6m−$2.2m−$1.1m
Diluted earnings per share-0.61-0.75-1.37-1.48-1.37-0.32-0.22-0.23

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets$22.8m$12.1m$18.6m$24.1m$39.0m$9.6m$660,286$811,634
Cash and short-term investments$20.8m$10.4m$16.8m$20.1m$36.9m$7.5m$303,320$400,694
Total liabilities$4.3m$4.8m$6.0m$5.2m$4.2m$3.4m$1.1m$1.8m
Debt$732,067$653,015$1.0m$1.3m$1.6m$1.3m$200,950$1.3m
Shareholders' equity$18.6m$7.3m$12.6m$18.9m$34.8m$6.2m−$449,856−$950,908
Shares outstanding33m27m16m12m10m11m10m5m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−$18.5m−$18.9m−$18.9m−$14.7m−$12.4m−$3.2m−$1.9m−$744,514
Capital spending−$2−$22,493−$15,358−$118,953−$94,212−$20,826−$13,723−$7,987
Free cash flow−$18.5m−$18.9m−$18.9m−$14.8m−$12.5m−$3.3m−$1.9m−$752,501

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——————$82,242—
Gross profit—−$21,303$4.9m−$22,817−$2.7m−$2.2m−$21,307−$275,408
Operating income−$4.7m−$5.4m−$4.5m−$4.8m−$5.1m−$4.4m−$3.3m−$4.5m
Net income−$4.7m−$5.6m−$4.5m−$5.3m−$5.8m−$4.5m−$3.8m−$4.5m
Diluted earnings per share-0.11-0.13-0.14-0.16-0.18-0.14-0.14-0.17
Cash from operations−$4.0m−$4.0m−$4.0m−$4.0m−$5.0m−$3.0m−$3.0m−$6.0m
Total assets$15.4m$18.7m$22.8m$11.0m$9.8m$11.6m$12.1m$14.4m
Cash and short-term investments$13.1m$16.5m$20.8m$8.8m$6.7m$9.1m$10.4m$12.0m
Debt$453,114$490,173$520,829$540,252$587,787$576,271$599,417$673,191
Shareholders' equity$11.3m$14.0m$18.6m$5.9m$3.7m$5.8m$7.3m$8.9m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income1.7%40.0%—
Net income4.7%41.3%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-5.3-1.6-1.3-1.2-2.2
Price to sales———147.5185.9

Share price return

Finished calendar years

20252024202320222021
Return163%-40%-14%-46%-55%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.